Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.53 |
| ▸ | FAP | Q12884 | 3/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 1/20 | 0.50 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.49 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.42 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370539 | 1.00 | FGFR1 (0.53) | FGFR1SLC22A6FAPABCB11POLA1 | |
| SCHEMBL21577310 | 1.00 | FGFR1 (0.53) | FGFR1SLC22A6FAPABCB11POLA1 | |
| SCHEMBL14839881 | 0.95 | ADCY5 (0.49) | FGFR1SLC22A6FAPABCB11POLA1 | |
| SCHEMBL2734847 | 0.94 | FGFR1 (0.55) | FGFR1SLC22A6FAPABCB11POLA1 | |
| SCHEMBL21991323 | 0.89 | SERPINA3 (0.53) | FGFR1SLC22A6FAPABCB11POLA1 | |
| Tenofovir Alafenamide SCHEMBL22139335 | 0.88 | FAP (0.60) | FAPBTN3A1CYP3A4 | |
| Tenofovir Alafenamide SCHEMBL3107149 | 0.88 | FAP (0.60) | FAPBTN3A1CYP3A4 | |
| Tenofovir Alafenamide SCHEMBL19467840 | 0.88 | FAP (0.60) | FAPBTN3A1CYP3A4 | |
| Tenofovir Alafenamide SCHEMBL14440384 | 0.88 | FAP (0.60) | FAPBTN3A1CYP3A4 | |
| Tenofovir Alafenamide SCHEMBL3107144 | 0.88 | FAP (0.60) | FAPBTN3A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11364257-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2022-06-21 | — | — | US | disclosed |
| US-20190350954-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | EMORY UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| EP-3094637-B1 | SOLID FORMS OF TENOFOVIR | GILEAD SCIENCES INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3235823-A1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | Gilead Sciences, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350954-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | TYMP, PNP, HPRT1 | FGFR1 3546/4885SLC22A6 2072/4885FAP 672/4885 |
| US-11364257-B2 | Phosphoramidates for the treatment of hepatitis B virus | TYMP, PNP, HPRT1 | FGFR1 3546/4885SLC22A6 2072/4885FAP 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.